I'm LongbridgeAI, I can summarize articles.Johnson & Johnson announced that the European Medicines Agency's CHMP recommends approving an indication extension for TALVEY (talquetamab). The recommendation supports using talquetamab combined with daratumumab, with or without pomalidomide, for adults with relapsed or refractory multiple myeloma who have received prior therapy. This approval is based on Phase 3 results showing significant survival benefits. If approved, this combination would be the only GPRC5D-targeting bispecific antibody option for second-line treatment.
Add 
as your preferred news source on Google
Add Now
Johnson & Johnson EMEA, a worldwide leader in multiple myeloma, announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends the approval of an indication extension of TALVEY (talquetamab).
The recommendation is for talquetamab plus daratumumab with or without pomalidomide for the treatment of adults with relapsed or refractory multiple myeloma (RRMM), who have received at least one prior therapy.
The CHMP recommendation is based on Phase 3 results where talquetamab and daratumumab, with or without pomalidomide, showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months.
If approved, TALVEY plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory second-line multiple myeloma treatment.
For comments and feedback contact: editorial@rttnews.com
Business News